While murine embryonic fibroblasts (MEFs) with Bax or Bak deleted displayed no defect in apoptosis signaling, MEFs with Bax and Bak double knockout (DKO) showed dramatic resistance to diverse apoptotic stimuli, suggesting that Bax and Bak are redundant, but essential regulators for apoptosis signaling. Chelerythrine has recently been identified as a Bcl-xL inhibitor that is capable of triggering apoptosis via direct action on mitochondria. Here we report that in contrast to classic apoptotic stimuli, chelerythrine is fully competent in inducing apoptosis in the DKO MEFs. Wild-type and DKO MEFs are equally sensitive to chelerythrine-induced morphological and biochemical changes associated with apoptosis phenotype. Interestingly, chelerythrine-mediated release of cytochrome C is rapid and precedes Bax translocation and integration. While the BH3 peptide of Bim is totally inactive in releasing cytochrome C from isolated mitochondria of DKO MEFs, chelerythrine maintains its potency and efficacy in inducing direct release of cytochrome C from these mitochondria. Furthermore, chelerythrine-mediated mitochondrial swelling and loss in mitochondrial membrane potential (∆Ψ m ) are inhibited by cyclosporine A (CsA), suggesting that mitochondrial permeability transition pore is involved in chelerythrine-induced apoptosis. Although certain apoptotic stimuli have been shown to elicit cytotoxic effect in the DKO MEFs through alternate death mechanisms, chelerythrine does not appear to engage necrotic or autophagic death mechanism to trigger cell death in the DKO MEFs. These results thus argue for the existence of an alternative Bax/Bakindependent apoptotic mechanism that involves CsA-sensitive mitochondrial membrane permeability.
While murine embryonic fibroblasts (MEFs) with Bax or Bak deleted displayed no defect in apoptosis signaling, MEFs with Bax and Bak double knockout (DKO) showed dramatic resistance to diverse apoptotic stimuli, suggesting that Bax and Bak are redundant, but essential regulators for apoptosis signaling. Chelerythrine has recently been identified as a Bcl-xL inhibitor that is capable of triggering apoptosis via direct action on mitochondria. Here we report that in contrast to classic apoptotic stimuli, chelerythrine is fully competent in inducing apoptosis in the DKO MEFs. Wild-type and DKO MEFs are equally sensitive to chelerythrine-induced morphological and biochemical changes associated with apoptosis phenotype. Interestingly, chelerythrine-mediated release of cytochrome C is rapid and precedes Bax translocation and integration. While the BH3 peptide of Bim is totally inactive in releasing cytochrome C from isolated mitochondria of DKO MEFs, chelerythrine maintains its potency and efficacy in inducing direct release of cytochrome C from these mitochondria. Furthermore, chelerythrine-mediated mitochondrial swelling and loss in mitochondrial membrane potential (∆Ψ m ) are inhibited by cyclosporine A (CsA), suggesting that mitochondrial permeability transition pore is involved in chelerythrine-induced apoptosis. Although certain apoptotic stimuli have been shown to elicit cytotoxic effect in the DKO MEFs through alternate death mechanisms, chelerythrine does not appear to engage necrotic or autophagic death mechanism to trigger cell death in the DKO MEFs. These results thus argue for the existence of an alternative Bax/Bakindependent apoptotic mechanism that involves CsA-sensitive mitochondrial membrane permeability.
Mitochondria are the major organelles involved in the signal transduction and biochemical execution of apoptosis (1) . Proteins of the Bcl-2 family are the central transducers of survival and apoptotic signals (2) . They act at mitochondria by regulating the permeability and integrity of the mitochondrial outer membranes, thereby controlling the release of apoptogenic factors. The Bcl-2 family consists of three major subfamilies of pro-survival and pro-apoptotic molecules. Members of BH3-only subfamily (Bim, Bad, Bid, Bik, Noxa, Puma and Hrk) serve as sentinels for the initiation of apoptosis by modulating the function of members of the other two multi-domain pro-survival (Bcl-2, Bcl-w, Mcl-1, Bcl-xL and A1/Bfl-1) or pro-apoptotic (Bax and Bak) subfamilies (3) (4) (5) .
A widely acknowledged paradigm of apoptotic signaling cascades suggests that apoptotic insults unleash one or more of the distinct BH3-only molecules and induce their translocation to the outer mitochondrial membrane (2, 6, 7) . In mitochondria, these proteins are thought to bind preferentially to the anti-apoptotic members of the Bcl-2 family (8) (9) (10) , hence serve to displace the multi-domain pro-apoptotic members from binding to the prosurvival molecules. The ratio between the levels of multi-domain pro-and anti-apoptotic members may thus play an important role in setting the rheostat for death responses to apoptotic insults (4, 11) . Some of the BH3-only molecules such as Bid and certain splicing isoforms of Bim are thought to have an additional role in promoting activation of the multi-domain pro-apoptotic molecules such as Bax and Bak (10, 12) .
Bax and Bak are essential but redundant regulators of the mitochondrial apoptotic signaling pathway (8, 9, 13) . Murine embryonic fibroblasts (MEFs) deficient in only one of the two molecules remain relatively normal in the execution of apoptosis signaling in response to a variety of apoptotic insults. Animals deficient in both molecules, however, display major abnormalities (14) . Furthermore, MEFs derived from bax and bak double-knockout mice (DKO) were found to be highly resistant to a wide variety of apoptotic stimuli, including overexpression of BH3-only molecules (8, 9, 13) .
Despite the profound apoptotic defects, the ability of some bax and bak double-knockout mice to survive into adulthood suggest the existence of other forms of cell death mechanism for directing proper development and maintaining tissue homeostasis by eliminating excess or damaged cells (14) . Interestingly, several recent reports have shown that certain chemical apoptotic stimuli are capable of engaging in alternative forms of cell death in the absence of Bax and Bak. For example, DNA alkylating agents appeared to induce a mix of both apoptotic and necrotic cell death in MEFs, whereas they induced mainly necrotic death in MEFs lacking both Bax and Bak (15) . Furthermore, while etoposide and staurosporine predominantly induce apoptosis in MEFs, they activate a caspase-independent cell death mechanism largely dependent on autophagy in the DKO MEFs (16) . Therefore, the DKO MEFs could serve as a valuable tool in delineating multiple cell death mechanisms that can be engaged by cytotoxic agents which may otherwise escape detection in cells with intact apoptotic machinery.
Chelerythrine, a benzophenanthridine alkaloid, is known to trigger apoptosis in a variety of tumour cells (17) . Recently, chelerythrine was identified by us as an inhibitory molecule that can block the heterodimerisation of the Bcl-xL and Bak BH3 peptide in a high-throughput screen of 107,423 extracts derived from natural products (18) . While etoposide, staurosporine and chelerythrine effectively triggered cytochrome C (Cyt. C) release from mitochondria in intact cells, only chelerythrine was able to induce Cyt. C release from isolated mitochondria (18) , suggesting that chelerythrine acts directly on mitochondria. In this study, we compared the cytotoxic activity of chelerythrine in the wild type (WT) and DKO MEFs in an attempt to further delineate the mechanism by which chelerythrine mediates its cytotoxic effect in mammalian cells. Interestingly, chelerythrine is cytotoxic to both cell types. Surprisingly, the morphological and biochemical features associated with chelerythrine-induced cytotoxicity in DKO MEFs are indistinguishable from those observed in the WT MEFs. These are consistent with apoptotic, rather than the autophagic or necrotic phenotypes associated with certain classic cytotoxic stimuli in the DKO MEFs. Furthermore, while chelerythrine and the Bim BH3 peptide are effective in triggering Cyt. C release from mitochondria isolated from WT MEFs, only chelerythrine remains active in mediating this effect on mitochondria isolated from the DKO MEFs. Chelerythrine induces mitochondrial swelling and loss of mitochondrial membrane potential (∆Ψ m ), and these effects are inhibited by cyclosporine A (CsA), suggesting the involvement of CsA-sensitive mitochondrial permeability transition pore (mPTP) components in both cell types. Taken together, these data strongly suggest that chelerythrine induces apoptosis in MEFs through a Bax-and Bakindependent mitochondrial mechanism that is distinct from the previously defined apoptosis gateway.
Experimental Procedures
Reagents and cell lines -SV40 T antigentransformed WT and DKO MEFs were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and antibiotics (100 mg of streptomycin/ml and 100 IU of penicillin/ml, Invitrogen). LipofectAMINE (Invitrogen) was used for transfections according to the user's manual. The caspase inhibitors N-Benzyloxycarbonyl-ValAla-Asp(O-Me) fluoromethyl ketone (z-VADfmk) and N-(2-quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)-methyl Ketone (Q-VD-OPH) were from Calbiochem. Staurosporine, etoposide, chelerythrine, camptothecin, 3-methyladenine (3MA) and cyclosporine A (CsA) were from Sigma. Anti-Cyt. C antibody was purchased from BD Sciences PharMingen. Antimyc antibody was from Santa Cruz Biotechnology. Antibody against HMG-B1 was from Abcam. Antibodies against actin and HSP60 were from Sigma. Cyt. C release and Bax translocation in intact cells -Cells were harvested and washed once with ice-cold phosphate-buffered saline (PBS). To separate the cytosolic fraction from other cellular components, cells were lysed for 5 min on ice in a solution consisting of 20 mM HEPES pH 7.2, 50 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 250 mM sucrose, 200 μg/ml of digitonin and protease inhibitors cocktail as described (19) . The organelles, cytoskeleton and membranes were pelleted by centrifugation at 12,000 rpm for 10 min at 4 °C. The supernatant (cytosol) was carefully removed and the pellet contains the mitochondria was solubilised in RIPA buffer [150 mM NaCl, 0.1% SDS, 10% sodium deoxycholate, 1% NP40, 2 mM EDTA and 10 mM HEPES (pH 7.3)] containing 'Complete' protease inhibitors cocktail. Protein content was determined by the Bradford reaction (Bio-Rad), and equivalent amount from each fraction were used for detection of Cyt. C release and Bax translocation using immunoblotting. Analysis of isolated mitochondria -Mitochondria were isolated from MEFs as previously described (20) . For in vitro Cyt. C release assays, cells were suspended in isolation buffer [320 mM sucrose, 1 mM EDTA, 50 mM HEPES (pH 7.5)] and disrupted by 20 expulsions through a 27-gauge needle. Disrupted cells were spun at 1,000 g for 10 min to remove cell debris and nucleus. The supernatants were centrifuged at 7,000 g for 10 min to pellet the heavy membrane fraction containing the mitochondria. The mitochondria-containing pellets were resuspended in assay buffer [250 mM sucrose, 2 mM KH 2 PO 4 , 5 mM sodium succinate, 25 mM EGTA and 10 mM HEPES (pH 7.5)] at 0.5 mg/ml. Equal amounts of mitochondria were treated with the indicated compounds for 15 min at room temperature, followed by centrifugation (20) . Cyt. C released into the supernatant was subjected to fractionation on 13.5% SDS-PAGE followed by western blotting analysis. For light scattering studies, mitochondrial isolated as described above were suspended in assay buffer (215 mM mannitol, 71 nM sucrose, 10 mM succinate and 10 mM HEPES, pH 7.4) (21). Changes in absorbance at 540 nM (A 540 ), indicating mitochondrial swelling as a consequence of mPTP opening, were measured, after addition of indicated compounds, using a microplate reader (Tecan). For dye retention assays, the mitochondrial suspension was incubated with JC-1 (100 ng/ml) for 10 min, then washed and resuspended in PBS; 5 min after the addition of indicated compounds, the level of JC-1 red fluorescence (FL2) retained by mitochondria was determined by flow cytometry (22) . Assessment of cell viability, cell proliferation and caspase3/7 activity -Cells were seeded onto 96 well plates. After 48 h, they were treated with the indicated concentrations of compounds. Cell death was assessed using WST assay, according to the supplier's protocols (Roche). For cell proliferation assay, cells were seeded onto 6-well dishes. After 2 h, they were treated with the indicated compounds in the presence and absence of 3MA (10 mM). The cells were then recovered and re-cultured in standard medium onto 96-well plates. Viable cell numbers were measured on the indicated days by WST assay. Caspase 3/7 activity was measured using a Caspase-Glo 3/7 kit from Promega. Reactive oxygen species (ROS) measurementCells were treated with the indicated concentrations of compounds for 16 h. After such treatment, cells were washed in PBS, and were loaded with 1 μM 5-(and 6-)chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester dye (CM-H 2 DCFDA; Molecular Probes) in PBS for 30 min at 37 °C as described (23 (Fig. 1A , panel e and f) and appearance of sub-G1 DNA (Fig. 1B) . The appearance of sub-G1 DNA was seen in DKO MEFs treated with chelerythrine, but not etoposide, staurosporine or camptothecin even though these compounds were fully effective in inducing sub-G1 DNA appearance in the WT MEFs ( Fig. 1B; data not shown). Progressive stages of apoptosis could easily be detected in the chelerythrine-treated MEFs. At 5 μM, chelerythrine induced the appearance of annexin V positive cells without an increase in propidium iodine (PI) staining at 16 h (Fig. 1C , panel b), indicative of early-stage apoptosis. Cells exposed to 5 μM chelerythrine for prolonged period (Fig. 1C , panel g and h) or treated with higher concentration of chelerythrine (Fig. 1C , panel c and d) became both annexin V and PI positive, presumably due to an increase in permeability of plasma membrane during the late stage of apoptosis. Moreover, chelerythrine was able to induce comparable caspase 3/7 activation in both WT and DKO MEFs (Fig. 1D ). In contrast, etoposide, staurosporine and UV irradiation were able to activate caspases 3/7 only in the WT MEFs (Fig.  1D ). The appearance of sub-G1 DNA in DKO MEFs upon chelerythrine treatment was clearly caspase-dependent, as the effect was abolished by pre-treatment with caspase inhibitor (zVADfmk) (Fig. 1E, upper panel) or over-expression of hXIAP (human X-linked inhibitor of apoptosis protein) (Fig. 1E , lower panel), a protein that is known to sequester and inhibit activated caspases (24) . Chelerythrine failed to induce caspase-8 activation in both WT and DKO MEFs (data not shown), suggesting that the cytotoxic effect of chelerythrine in MEFs is not attributable to the extrinsic apoptosis signaling pathway. Consistent with the notion that the efficacy of chelerythrine in engaging mitochondrial apoptosis signaling is not affected by the absence of Bax and Bak, the kinetics and efficacy of Cyt. C release from mitochondria to cytosol triggered by chelerythrine in both WT and DKO MEFs were similar (Fig. 3A) . Interestingly, chelerythrine appeared to cause rapid release of Cyt. C (Fig. 3A, right panel) . Since translocation of Bax from cytosol to mitochondria and subsequent integration into outer mitochondrial membrane are thought to be the key signaling events preceding Cyt. C release upon apoptosis induction (20), we next compared the kinetics of these two events upon treatment with chelerythrine in WT and DKO MEFs. Surprisingly, chelerythrine-mediated Bax translocation and integration in the WT MEFs occurred at much slower kinetics than the Cyt. C release (Fig. 3B, left panel) . In the DKO MEFs, despite the absence of Bax and Bak, the rapid kinetics of Cyt. C release was unaltered in response to chelerythrine (Fig. 3B, right panel) . In contrast, staurosporine-induced Bax activation in WT MEFs coincided with Cyt. C release (Fig.  S2A ). DKO MEFs were significantly resistant to staurosporine-induced Cyt. C release (Fig. S2B) , confirming the critical role of the Bax/Bak gateway in mediating staurosporine-induced apoptosis.
Chelerythrine remains fully active in inducing
BH3-only molecules are thought to integrate and relay apoptosis signals to mitochondria. Polypeptides consisting of amino acids representing the sequence of the BH3 domains are sufficient to trigger the direct release of Cyt. C from isolated mitochondria (10) . Certain chemical inhibitors of pro-survival members of Bcl-2 family including chelerythrine are thought to act as mimetic of the BH3-only molecules (18, 22, (25) (26) (27) (28) (29) (30) . Chelerythrine was indeed shown to be competent in releasing Cyt. C from isolated mitochondria (18) . Consistent with the observation that BH3 only-molecules are inactive in triggering apoptosis in DKO MEFs, the BH3 peptide encompassing the BH3 domain of Bim, was effective only in releasing Cyt. C from mitochondria isolated from WT, but not DKO cells (Fig. 3C, left panel) . On the contrary, chelerythrine triggered the release of Cyt. C from mitochondria isolated from both WT and DKO MEFs with similar efficacy (Fig. 3C , right panel), suggesting that chelerythrine may act through a mechanism distinct from that of the BH3-only molecules.
Chelerythrine induces cyclosporine A-sensitive mitochondrial permeability transition independent of Bax and Bak. Two major mechanisms have been proposed to account for the release of Cyt. C from mitochondria. One involves activation and oligomerisation of Bax and Bak, followed by direct pore formation by the oligomers (11, 31) . Another proposed mechanism is the interaction of multi-domain pro-apoptotic Bcl-2 family members with components of the mitochondrial permeability transition pore (mPTP), such as the voltagedependent anion channel (VDAC), the adenine nucleotide translocator (ANT) and cyclophilin D (CypD), which results in mitochondrial depolarization and swelling, followed by mitochondrial outer membrane rupture and release of the inter-membrane content (32) . Since chelerythrine-mediated release of Cyt. C does not appear to be dependent on Bax and Bak, its effect on Cyt. C release may therefore involve certain components described in the latter mechanism. We next checked whether the ability of chelerythrine to induce loss in ∆Ψ m in MEFs is affected by the mPTP inhibitor cyclosporine A (CsA), which can act as a pseudo-substrate of CypD that prevents it from interacting with the mPTP (32) . Pre-treatment of WT (Fig. 4A, left panel) and DKO MEFs (Fig.  4A, right panel) with CsA was able to inhibit the increase in loss of ∆Ψ m induced by chelerythrine, suggesting chelerythrine may affect the mitochondrial integrity, at least in part, via the disruption of mPTP components.
To investigate further the role of mPTP in mediating the effect of chelerythrine, we used isolated mitochondria from WT and DKO MEFs to study its effect in causing mitochondrial swelling, which is indicative of the opening of mPTP. Direct addition of chelerythrine to mitochondria isolated from WT (Fig. 4B , left panel) and DKO (Fig. 4B, right panel) MEFs caused a fall in light attenuance in a dosedependent manner, characteristic of largeamplitude swelling. In contrast, classic apoptotic stimuli (etoposide and staurosporine) failed to induce swelling of mitochondria isolated from both WT and DKO MEFs (data not shown). Bim BH3 peptide, on the other hand, was effective in inducing swelling of mitochondria isolated from WT MEFs (Fig. 4C, left panel) , but not DKO MEFs (Fig. 4C, right panel) , which supports the recent observation that Bim BH3 peptides can directly regulate Bax-mediated mitochondrial membrane permeabilisation (33) . Since cherythrine-induced loss of ∆Ψ m was inhibited by CsA in intact cells, we next examined whether mitochondrial swelling can also be blocked by CsA. CsA completely attenuated chelerythrine-induced swelling of mitochondria isolated from WT (Fig. 4D , left panel) and DKO MEFs (Fig. 4D, right panel) , providing further evidence to argue that chelerythrine induces mPTP opening by affecting mPTP components.
We also tested the effect of chelerythrine on mitochondrial membrane potential in isolated mitochondria. Isolated mitochondria were loaded with the ΔΨ m -sensitive JC-1 probe before treatment and mitochondrial labeling was determined by flow cytometry. Similar to the data in intact cells, chelerythrine induced a loss of ΔΨ m in both isolated mitochondria from WT (Fig. 4E, left panel) and DKO MEFs (Fig. 4E,  right panel) . Consistent with the mitochondrial swelling observations, pre-treatment of the mitochondria with CsA resulted in inhibition of loss of ΔΨ m induced by chelerythrine (Fig. 4E) . Collectively, our data indicate that chelerythrine has a direct effect on the CsA-sensitive, but Baxand Bak-independent mPTP.
Chelerythrine does not cause necrotic death.
Although it has been well documented that the CsA-sensitive mPTP plays a role in mitochondrial apoptotic signaling, recent data from CypD-deficient mice showed that CypDdeficient mitochondria did not undergo CsAsensitive mPTP and loss of ∆Ψ m . These CypD deficient MEFs were resistant only to necrotic stimuli, suggesting that necrosis, but not apoptosis, is regulated by the CsA-sensitive mPTP (34) . Since chelerythrine-induced loss of ΔΨ m and mitochondrial swelling can be inhibited by CsA (Fig. 4) , it raises the question whether chelerythrine-mediated cytotoxicity may, at least in part, associate with necrotic mechanism. To examine necrosis as a contributing factor of chelerythrine-mediated cytotoxicity, we first compared the cytotoxicity of chelerythrine and the necrotic death resulted from exposure to high concentration of hydrogen peroxides (500 μM H 2 O 2 ) (34, 35). As expected, high level of H 2 O 2 failed to induce apoptosis in DKO MEFs as indicated by the absence of caspases activation, sub-G1 DNA appearance and nuclear fragmentation (data not shown). H 2 O 2 , however, was capable of triggering ROS production ( Fig. 5A; Fig. S3A ) and cell death (Fig. 5B) . While chelerythrine was also capable of elevating ROS level, a broad spectrum caspase inhibitor (Q-VD-OPH) was effective in ablating chelerythrine-induced, but not H 2 O 2 -induced ROS elevation ( Fig. 5A; Fig. S3A ) and cell death (Fig. 5B) , suggesting that mitochondria-derived ROS originated from caspase feedback mechanism may play a role in chelerythrine, but not H 2 O 2 -induced cell death in MEFs.
Interestingly, another regulated form of necrotic death that is independent of Bax/Bak mitochondrial apoptosis pathway but is dependent on poly(ADP-ribose) polymerase (PARP) activation has recently been described in cells treated with alkylating DNA damaging agents (15) . In agreement with the reported data, PARP inhibitor (DPQ) was effective in partial rescue of cell death induced by alkylating DNA damage agent mechlorethamine hydrochloride (nitrogen mustard) in WT (Fig. S3B, left panel) and DKO MEFs (Fig. 5C, left panel) . DPQ, however, did not appear to have a significant effect on blocking chelerythrine-mediated cytotoxicity in either WT (Fig. S3B, right panel) or DKO MEFs (Fig. 5C, right panel) . It has been reported that extracellular high-mobility group B1 protein (HMG-B1) is responsible for the inflammatory response of cell necrosis (36) . Necrotic death induced by nitrogen mustard involves the release of HMG-B1 into the extracellular environment which acts as a ligand for the monocyte/macrophage scavenger receptor RAGE (15) . Therefore, cells that were treated with nitrogen mustard or chelerythrine were also evaluated for their effect on affecting the localization of HMG-B1. HMG-B1 was found in the extracellular environment of cells treated with nitrogen mustard (Fig. 5D, left  panel) . In contrast, chelerythrine failed to induce the release of HMG-B1 into the extracellular environment (Fig, 5D, right panel) . Together, these data suggest that chelerythrine-mediated cell death does not involve the necrotic mechanism associated with caspase-independent reactive oxygen species or alkylating agent.
Chelerythrine-induced cytotoxicity is not attributable to autophagy. It has recently been shown that cytotoxic drugs could have dual mechanisms in conferring cytotoxicity in mammalian cells. For example, when the apoptotic effect of etoposide is completely lost in the DKO MEFs, it remains cytotoxic to these cells (16) . Electron microscopic and biochemical studies revealed that the etoposide-induced cell death in DKO MEFs was associated with autophagosomes/autolysosomes and was effectively suppressed by inhibitors of autophagy, including 3-methyl adenine (3MA) in these cells (16) . Surprisingly, the autophagic death mediated by etoposide appears to be positively regulated by Bcl-2 and Bcl-xL (16) . Since chelerythrine targets Bcl-xL (18, 37) , autophagic mechanism can potentially be involved in chelerythrine-mediated cytotoxicity in the DKO MEFs. We therefore tested the ability of 3MA to inhibit chelerythrine-induced cell death. Similar to reported results, 3MA was effective in preventing the rounding up of DKO MEFs upon etoposide treatment (Fig. 6A) .
However, 3MA appeared to be totally ineffective in blocking the effect of chelerythrine on both the WT (data not shown) and DKO MEFs (Fig.  6A) . The ability of chelerythrine-or etoposidetreated cells to proliferate was also investigated. 3MA treatment did not rescue the DKO MEFs treated with chelerythrine, whereas it significantly enhanced the proliferating capacity of etoposide-treated cells (Fig.  6B) . Furthermore, 3MA also failed to improve the viability of chelerythrine-treated cells as determined using WST assay (data not shown). Cells undergoing autophagic death are known to have compromised plasma membrane integrity. The ability of DKO MEFs to exclude the DNA dye 7AAD upon chelerythrine or etoposide treatment in the presence or absence of 3MA was evaluated. Etoposide-treated DKO MEFs were able to exclude 7AAD in the presence of 3MA (Fig. 6C, right panel) , whereas the plasma membrane of chelerythrine-treated WT (data not shown) and DKO MEFs (Fig. 6C, left panel) was still permeable to 7AAD with the 3MA treatment. During the autophagic process, microtubule light chain-3 (LC3) concentrates in autophagosomes, which would appear as punctuate rather than diffuse staining patterns under immunofluorescence microscopy (38) . Diffuse cytoplasmic localization of transiently expressed LC3 was observed in healthy and chelerythrine-treated DKO MEFs, whereas etoposide-and staurosporine-treated DKO MEFs showed punctuate fluorescence staining of LC3 under immunofluorescence microscopy (Fig.  6D) . Etoposide-and staurosporine-induced aggregation of LC3 was inhibited by 3MA. In contrast, 3MA had no effect on LC3 localisation either in healthy or chelerythrine-treated DKO MEFs (Fig. 6D ). In addition, 3MA was also unable to block chelerythrine-induced mitochondrial membrane potential change (Fig.  S4) . Together, these data reveal no evidence that chelerythrine can mediate autophagic death in either the WT or DKO MEFs.
DISCUSSION
Chelerythrine was identified as Bcl-xL inhibitor from a high throughput screen and was subsequently shown that it can interact with the BH groove instead of the classic BH3-binding cleft when many other chemical inhibitors of Bcl-2/Bcl-xL are known to bind. Chelerythrine can act on isolated mitochondria from tumor cells for triggering the direct release of Cyt. C (18) . In this study, we characterized and compared the cytotoxic mechanism of chelerythrine in both WT and DKO MEFs. In contrast to other established chemical apoptotic stimuli, chelerythrine appears to induce classic apoptotic phenotypes in both cell types with similar kinetics and efficacy. Although chelerythrine was capable of inducing Bax integration in WT MEFs, this event occurred only after a long delay (~10 h after Cyt. C release), suggesting that Bax activation in the WT MEFs may occur via positive feedback mechanism triggered by downstream apoptosis events. Furthermore, the kinetics of Cyt. C release from mitochondria isolated from both WT and DKO MEFs were almost identical, suggesting that Bax activation may not be a major contributing factor in mediating the apoptotic phenotypes triggered by chelerythrine. Indeed, the rapid release of Cyt. C that preceded Bax activation and the inhibitory activity of CsA towards mitochondrial swelling strongly suggest that chelerythrine-induced apoptosis in MEFs is predominantly due to the CsA-sensitive mPTP opening instead of the Bax/Bak-mediated permeabilization mechanism.
Since chelerythrine is able to interact with Bcl-xL and acts directly on mitochondria (18) , it is tempting to speculate that the effect of chelerythrine on the mPTP is related to Bcl-2/Bcl-xL inhibition. Although the molecular mechanism by which Bcl-2/Bcl-xL inhibits mPTP is still controversial, several independent evidence have emerged demonstrating that these proteins can interact with sessile mitochondrial proteins, including ANT (39) and VDAC (40) . In vitro, over-expression of Bcl-2 in cells or the addition of Bcl-2 to isolated mitochondria suppressed the mPTP induced by a variety of apoptotic insults (39, 41, 42) . Therefore, it is plausible that the inhibition of Bcl-2/Bcl-xL by chelerythrine might result in the sensitization of the mitochondrial membranes permeability via mPTP components, release of Cyt. C and functional collapse of the organelle and apoptosis. However, alternative mechanisms such as activation of other unidentified mitochondrial targets that are dependent on mPTP components by chelerythrine are certainly possible and remain to be explored.
While we were investigating the Baxand Bak-independent apoptotic mechanism triggered by chelerythrine, two studies were published to suggest that two distinct apoptotic insults, such as gossypol and A23187/ arachidonic acid (ArA), are capable of inducing apoptosis in the DKO MEFs. In contrast to chelerythrine, the apoptotic effects of gossypol (Fig. S5A ) and the A23187/ArA (43) are significantly weaker in the DKO than the WT MEFs, suggesting that the apoptotic effects emulated from these stimuli may, in part, still be dependent on the Bax/Bak gateway. Furthermore, our data showed that neither gossypol (Fig. S5 , B and C) nor A23187/ArA (43) were effective in triggering Cyt. C release and swelling in isolated mitochondrial preparations, suggesting that unlike chelerythrine, these compounds do not act directly on mitochondria to mediate their apoptotic effect in MEFs. In fact, our results are in disagreement with a previous report showing that gossypol was able to induce Cyt. C release from mitochondria isolated from DKO MEFs (44) . In the study by Lei and colleagues (44) , mitochondria were incubated for 1 h in a buffer devoid of calcium chelator EGTA whereas our experiments were performed for 30 min in a buffer containing EGTA. This may explain why their mitochondrial preparation was more sensitive to gossypol, as it has been documented that mitochondria have a tendency to release spontaneously high levels of Cyt. C in the absence of EGTA (45) . The mechanistic basis for the mitochondrial effects of these drugs also appears to be different as gossypol-and A23187/ArA-induced Cyt. C release are insensitive to CsA and independent of mPTP opening (43, 44) , whereas the mitochondrial event induced by chelerythrine is mediated by CsA-sensitive mPTP.
Recently, the ability of several chemical inhibitors of Bcl-2/Bcl-xL (ABT-737, BH3I-1, HA14-1, antimycin A, gossypol and chelerythrine) to induce cell death in the DKO MEFs has also been investigated (46) . Except ABT-737, these inhibitors appeared cytotoxic to DKO MEFs. However, the nature of the cytotoxic mechanisms associated with each of these inhibitors in DKO MEFs was not known as detailed phenotypic and molecular characterizations were not performed. It was concluded from that study that only ABT-737 qualifies as a genuine chemical BH3 mimetic as it behaves just like BH3-only proteins in that they fail to induce apoptosis in the absence of Bax and Bak. Surprisingly, our in-depth characterization and comparison of cytotoxic mechanism of chelerythrine in WT and DKO MEFs provides strong and comprehensive evidence to suggest that chelerythrine is an apoptotic agent that acts through Bax/Bakindependent mitochondrial mechanism. As revealed by NMR and modeling analysis, chelerythrine can induce a global change in the Bcl-xL protein structure through direct interaction with the BH groove (37) instead of the classic BH3 domain binding cleft where BH3 peptides and ABT-737 are shown to dock (26) . This finding would suggest that chelerythrine may confer its inhibitory action on Bcl-xL by directly or indirectly competing with unknown regulatory proteins. It would be of interest to investigate further on the structure activity relationship of chelerythrine-related compounds on their apoptotic effect in the DKO MEFs versus their binding and inhibitory activities on pro-survival members of Bcl-2 family to gain further insight on whether the Bax/Bakindependent pro-apoptotic mechanism is dependent on direct interaction with the prosurvival molecules.
Chelerythrine has recently been shown to display biphasic effect on mitochondrial respiration with energy uncoupling at low concentration and respiration inhibition at high concentration (47) . Based on this study, chelerythrine-induced apoptosis in MEFs might just be a simple consequence of mitochondrial toxicity.
Interestingly, in contrast to chelerythrine, respiratory complex IV inhibitor (sodium azide) (48) and uncoupler of mitochondrial oxidation (carbonyl cyanide p trifluoromethoxyphenylazone) (49) that directly interfere energy coupling, were cytotoxic to WT, but not the DKO MEFs (Fig. S6) . These data would serve to argue that the main mode of action of chelerythrine in causing cytotoxicity in MEFs is unlikely due to its effect on mitochondrial respiration.
It was suggested that Bax and Bak might share a redundant function that suppresses tumorigenicity through the independent ability of either of these proteins to initiate apoptosis in response to oncogenic transformation (9) . Using transformed primary baby kidney epithelial cells (BMKs), Degenhart and colleagues also showed that Bax and Bak function to suppress tumorigenesis and their deficiency resulted from gene mutation was found to be prevalent in tumor cells detected in metastatic sites in a mouse tumor model (50). Therefore, designing specific strategies to overcome survival of the tumor cells in the absence of Bax and Bak function may provide novel opportunities in anticancer drug discovery. Indeed, it has been shown that chelerythrine induces tumor growth delays in vivo and appears to have a minimum adverse effect in mice (51). In this respect, chelerythrine may have the potential to serve as a lead compound to support exploration of the Bax/Bak-independent mechanism as a molecular target for anticancer drug development. 
